Accused of stealing Teva secrets, Apotex CEO exits abruptly even as founder's death ruled homicide

The turmoil at Canada’s largest homegrown pharma company, generics maker Apotex, continues with the resignation of CEO Jeremy Desai even as the company deals with the fallout from the murders of the company’s founder and his wife. Apotex said on Friday that Desai had resigned and was being replaced by vice chairman and former CEO Jack Kay. Apotex global generics president Jeff Watson, a 25-year veteran of the company, has been appointed president and chief operating officer. The resignation of Desai comes six months after Teva filed a lawsuit against him and Apotex claiming that for two years Desai received copies of Teva trade secrets from his girlfriend, Barinder Sandhu, who before her 2016 departure was Teva’s chief of regulatory affairs for its American generics business.